BTIG Research upgraded shares of bluebird bio, Inc. (NASDAQ:BLUE) from a neutral rating to a buy rating in a report released on Thursday morning, MarketBeat.com reports. BTIG Research currently has $177.00 price objective on the biotechnology company’s stock.
BLUE has been the topic of a number of other research reports. Zacks Investment Research lowered bluebird bio from a buy rating to a hold rating in a research note on Tuesday, July 18th. Cantor Fitzgerald reaffirmed a sell rating and set a $39.00 price objective on shares of bluebird bio in a research note on Thursday, September 28th. Evercore ISI raised bluebird bio from an in-line rating to an outperform rating and set a $102.00 price objective on the stock in a research note on Monday, October 16th. BMO Capital Markets raised their price target on bluebird bio from $134.00 to $162.00 and gave the stock a buy rating in a research note on Monday, October 30th. Finally, Goldman Sachs Group, Inc. (The) reissued a buy rating and issued a $186.00 price target on shares of bluebird bio in a research note on Friday, October 6th. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and fourteen have assigned a buy rating to the company’s stock. The company has a consensus rating of Buy and a consensus target price of $131.05.
bluebird bio (NASDAQ:BLUE) traded up $2.20 on Thursday, hitting $156.25. The company had a trading volume of 1,240,575 shares, compared to its average volume of 816,660. bluebird bio has a fifty-two week low of $41.25 and a fifty-two week high of $164.80.
bluebird bio (NASDAQ:BLUE) last posted its quarterly earnings data on Wednesday, November 1st. The biotechnology company reported ($1.73) EPS for the quarter, missing analysts’ consensus estimates of ($1.68) by ($0.05). The company had revenue of $7.71 million for the quarter, compared to analyst estimates of $8.47 million. bluebird bio had a negative net margin of 883.18% and a negative return on equity of 28.79%. The firm’s revenue was up 397.4% on a year-over-year basis. During the same period in the previous year, the business earned ($2.07) EPS. research analysts expect that bluebird bio will post -6.76 EPS for the current year.
ILLEGAL ACTIVITY NOTICE: This report was first published by Community Financial News and is owned by of Community Financial News. If you are viewing this report on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark laws. The legal version of this report can be accessed at https://www.com-unik.info/2017/11/05/bluebird-bio-inc-blue-upgraded-at-btig-research.html.
In related news, Director Daniel Lynch sold 500 shares of the firm’s stock in a transaction dated Thursday, August 31st. The stock was sold at an average price of $120.00, for a total transaction of $60,000.00. Following the sale, the director now directly owns 3,300 shares in the company, valued at approximately $396,000. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Jeffrey T. Walsh sold 1,250 shares of the firm’s stock in a transaction dated Thursday, August 10th. The shares were sold at an average price of $95.41, for a total value of $119,262.50. Following the sale, the insider now owns 28,555 shares in the company, valued at $2,724,432.55. The disclosure for this sale can be found here. Insiders sold a total of 186,268 shares of company stock worth $24,366,623 over the last ninety days. Corporate insiders own 3.90% of the company’s stock.
Large investors have recently made changes to their positions in the stock. Quantitative Investment Management LLC raised its holdings in shares of bluebird bio by 1,193.8% during the 2nd quarter. Quantitative Investment Management LLC now owns 104,800 shares of the biotechnology company’s stock valued at $11,009,000 after buying an additional 96,700 shares during the period. State of Wisconsin Investment Board purchased a new stake in shares of bluebird bio during the 2nd quarter valued at about $3,257,000. Winfield Associates Inc. raised its holdings in shares of bluebird bio by 6.1% during the 2nd quarter. Winfield Associates Inc. now owns 2,822 shares of the biotechnology company’s stock valued at $296,000 after buying an additional 162 shares during the period. OMERS ADMINISTRATION Corp purchased a new stake in shares of bluebird bio during the 2nd quarter valued at about $1,061,000. Finally, Janus Henderson Group PLC purchased a new stake in shares of bluebird bio during the 2nd quarter valued at about $5,252,000.
bluebird bio Company Profile
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
What are top analysts saying about bluebird bio Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for bluebird bio Inc. and related companies.